Therefore, these results further demonstrated in vivo that miR-181c inhibiting ST8SIA4 and its downstream PI3K/AKT pathways is one potential mechanism to overcome drug resistance in CML. This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.